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again formulated (FVIII <1%, inhibitor titer 19 BU) and the patient
was treated with the same anti-hemorrhagic and immunosuppressive
treatment, reaching CR on day +20. In addition, the patient received
anti-viral drugs (lopinavir-ritonavir 400 mg/twice daily) and non-
invasive mechanical ventilation with oxygen as treatment for Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection,
leading to the resolution of the disease on day +14.
In this case, the first reported in literature, the re-appearance of
AHA was triggered by acute SARS-Cov-2 infection. This finding
is particularly interesting considering the close interaction
between SARS-Cov-2 and the hemostatic system.4 The AHA cases
associated with other viral infections, including hepatitis B and C
viruses, have also been described.3 The recent association
between immune thrombocytopenic purpura and COVID-19 fur-
ther strengthens the virus-induced immune dysregulation,5 which
could have played a key role in the pathogenesis of AHA. We
therefore recommend a daily coagulation monitoring (APTT) in
patients admitted with acute COVID-19 infection and the inhibi-
tor search (through a mixing test) in those cases with otherwise
unexplained onset or worsening of the hemorrhagic picture and/or
aPTT prolongation.
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SARS-CoV-2 infection in beta
thalassemia: Preliminary data
from the Italian experience
To the Editor:
Patients with pre-existent chronic morbidities are likely to be more
severely affected by SARS-Cov2 infection, but no data are available
regarding Thalassemic Syndromes (TS). Note, TS and hemoglobin vari-
ants represent, according to WHO, one of the most frequent causes
of anemia, affecting more than 7% of the world population.1 Thalasse-
mic Syndromes are classified in either transfusion-dependent thalas-
semia (TDT) or non-transfusion-dependent thalassemia (NTDT).
Infectious complications, mainly from bacteria, constitute a common
cause of mortality and morbidity in TS. Stress erythropoiesis, iron
overload, splenectomy and adrenal insufficiency among others may
contribute to increase susceptibility to infection.2
To verify the impact of SARS-CoV-2 infection on TS, we set-up a
specific survey by electronic Case Report Form (eCRF).3 Inclusion
criteria require at least 15 days of follow-up from either the onset of
symptoms or SARS-CoV2 positivity. The survey was approved by
Ethics Committee and eCRF was shared with the Centers of Italian
Hemoglobinopathies Network. The “Società Italiana Talassemie ed
Emoglobinopatie” (SITE), has estimated the presence in Italy of
approximately 5000 TDT and 1900 NTDT patients.3
As of 10 April 2020, 11 cases of TS and COVID-19 have been
collected (see supplementary information). All the reported patients
are in Northern Italy, where the rate of infection is higher, reflecting
the national epidemiology.
The mean age is 44 ± 11 years (range 31-61 years) and 55%
(6/11) are females. Ten patients are TDT, and one is NTDT. All the
patients have thalassemia associated comorbidities, eight are
splenectomized, and one patient (#9 in the supplementary table) has
pulmonary hypertension treated with sildenafil. The likely source of
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infection has been detected in 55% (6/11) of cases: two had contacts
with COVID-19 positive subjects, and four had occupational exposure
(three are nurses working in hospital or assisted living facilities).
Three patients were asymptomatic. One patient (#3 in supple-
mentary information) was admitted for high fever and bone marrow
hypoplasia, lymphopenia, and agranulocytosis (on treatment with def-
eriprone) and tested positive at the third swab. Six out of 11 were
hospitalized, but no one required mechanical ventilation. The patient
with more severe symptoms who required more intensive ventilation
support with continuous positive airway pressure (CPAP) has a history
of diffuse large B-cell lymphoma, treated with chemotherapy in the
previous year, currently in complete remission. Of the six people
admitted to the hospital, only three received supposedly specific
treatment for COVID-19: one hydroxychloroquine (HCQ), one HCQ
plus ritonavir/darunavir, and one HCQ plus anakinra. Patient #3 did
not receive HCQ due to concomitant therapy with amiodarone and an
increased risk of life-threatening arrhythmia. The clinical course ranged
from 10 to 29 days. Ten patients have clinically recovered and are on
a daily remote phone call follow-up. Splenectomy which was present
in 8/11 patients did not seem to affect the clinical course. Of note,
except for the patient with myelosuppression, no increase in blood
requirement was observed. When luspatercept treatment was halted
in the NTDT patient, hemoglobin fell from 110 to 82 g/L, a value simi-
lar to the pre-luspatercept period. Neither death nor severe SARS or
signs of cytokines storm were observed in these 11 subjects, which
may be surprising, taking into account the mean age and the presence
of severe comorbidities.
Our data, although preliminary, do not indicate increased severity
of COVID-19 in TS. A larger number of cases needs to be collected to
define the impact of this new infection and its outcome in these frag-
ile patients.
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Management of CLL patients
early in the COVID-19
pandemic: An international
survey of CLL experts
To the Editor:
The coronavirus disease 2019 (COVID-19) pandemic caused by the
novel coronavirus (SARS CoV-2) has posed an unprecedented health
emergency, especially to those with older age or comorbid medical
conditions.1 Patients with chronic lymphocytic leukemia (CLL) have a
median age of about 70 years at diagnosis, and the majority suffer
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